Ann: Actinogen awarded UK Innovation Passport for Xanamem, page-65

So tell me CS, ACW have no biomarkers they can measure? I think maybe you should revisit PET scans & blood biomarkers & potentially functional endpoints in AD they will be measuring in clinical trials. If you are disappointed in an ILAP approval including consultation with NICE & MHRA, I’m sorry to say maybe you have been sniffing the paint fumes too much & not reading enough for available AD biomarkers & why EXPERT panels have approved this.

It’s actually a very positive thing & even though you said you are feeling very negative about things going on in your life, it’s not about you & to dump on this board, while I’m sure most of us have empathy, I do, but there is a limit.

An ASX stock, whatever you have chosen to do with your shares is not anyone else’s problem or business. I’m really not sure about the clown show here with you & @IndexInvestor. Going on for years. Stop tagging me in your shit posts you can work out for yourselves & weird stuff OK.

ILAP Passport provides a flexible pathway for fast track approval, as does the FDA in a clinically unmet need. This is bad? How? 3-4 years earlier getting drugs into patients via expedited approvals? You tell me & how Xanamem was approved for the ILAP passport in conjunction with NICE & MHRA? Do you think I’m going to listen to you & Indexinvestor over the last 5 or so years of constant dribble about dosing & PET scans or KOL on Regulatory panels? Sure you are disappointed, because you were wrong & probably sold red. Don’t paint me that way.

We will know more throughout Phase 2 trials for ACW.
Until then, stop tagging me if you are going to go on with dribble with another poster here, both of you. Easily available information to source from the FDA & UK. Check NHIR Observatory for updates.

Other than that DYOR